Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Cash Flows

v3.24.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Cash Flows From Operating Activities    
Net income (loss) $ 802 $ (21,958)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:    
Depreciation and amortization 1,026 2,560
Interest accretion expense 112 158
Goodwill impairment 8,433
Intangible asset impairment 3,964
Amortization of deferred financing fees 42 60
Stock-based compensation 630 1,258
Amortization on operating lease right of use asset 575 942
ESPP expense 46
Change in fair value of note payable 678 1,223
Deferred income taxes (93)
Change in fair value of contingent consideration 7 (223)
Other gains and expenses, net (71)
Other changes in operating assets and liabilities:    
Accounts receivable 49 (133)
Other current assets (89) (216)
Other long-term assets 34
Accounts payable 489 (735)
Accrued salaries and bonus 513 (1,421)
Accrued liabilities (936) (549)
Operating lease liabilities (376) (1,142)
Long-term liabilities 267 171
Net cash provided by (used in) operating activities 3,789 (7,692)
Cash Flows From Investing Activity    
Proceeds from sale of Interpace Pharma Solutions, net 383 6,528
Purchase of property and equipment (470) (322)
Net cash (used in) provided by investing activities (87) 6,206
Cash Flows From Financing Activities    
Issuance of common stock, net of expenses 108
Payment of BroadOak terminal payment (2,500)
Proceeds from convertible debt issuance 2,000
Payments on line of credit (2,500)
Borrowings on line of credit 1,000
Cash paid for repurchase of restricted shares (32) (108)
Net cash (used in) provided by financing activities (5,032) 3,000
Net (decrease) increase in cash and cash equivalents (1,330) 1,514
Cash and cash equivalents from continuing operations – beginning 4,828 2,922
Cash and cash equivalents from discontinued operations – beginning 392
Cash and cash equivalents – beginning 4,828 3,314
Cash and cash equivalents from continuing operations – ending 3,498 4,828
Cash and cash equivalents from discontinued operations – ending
Cash and cash equivalents – ending $ 3,498 $ 4,828